CASSAVA SCIENCES INC. - COMMON STOCK

Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease

06 Dec 2022 06:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Closing of $50 Million Registered Direct Offering

22 Nov 2022 09:29:58 By Nasdaq GlobeNewswire

Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock

18 Nov 2022 10:30:58 By Nasdaq GlobeNewswire

Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates

07 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign

03 Nov 2022 06:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Expansion of Leadership Team

27 Oct 2022 06:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Initiation of an Open-label Extension Study

13 Oct 2022 06:15:00 By Nasdaq GlobeNewswire

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

08 Sep 2022 06:15:00 By Nasdaq GlobeNewswire

No Evidence of Data Manipulation in Science Publication on Simufilam

18 Aug 2022 06:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study

03 Aug 2022 06:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Responds to Media Reports

27 Jul 2022 10:36:21 By Nasdaq GlobeNewswire

Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program

05 May 2022 06:00:03 By Nasdaq GlobeNewswire

Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference

25 Apr 2022 06:00:00 By Nasdaq GlobeNewswire

Webcast Details for Cassava Sciences’ Upcoming Fireside Chat

04 Apr 2022 06:00:01 By Nasdaq GlobeNewswire

Cassava Sciences Announces Fireside Chat and Presentation Tuesday, April 5th

30 Mar 2022 06:00:01 By Nasdaq GlobeNewswire

Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates

28 Feb 2022 13:03:00 By Nasdaq GlobeNewswire

FDA Denies Citizen Petitions Filed on Behalf of Short Selling Clients

10 Feb 2022 13:07:38 By Nasdaq GlobeNewswire

Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam in Alzheimer’s Disease

23 Dec 2021 06:00:00 By Nasdaq GlobeNewswire

Science Journal Finds No Evidence to Support Claims of Data Manipulation in 2005 Publication

21 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Patients with Alzheimer’s Disease

18 Nov 2021 06:15:00 By Nasdaq GlobeNewswire